SLC5A2 and chronic kidney disease: Major strengths of this network meta-analysis are of the follwowing: first and foremost, it was the first to investigate the effect of finerenone, SGLT-2 inhibitors and GLP-1 RA on cardiovascular and renal outcomes in patients with T2DM and CKD.